OUTCOME OF ADVANCED CHRONIC LYMPHOCYTIC LEUKEMIA FOLLOWING DIFFERENT FIRSTLINE- AND RELAPSE-THERAPIES: A METAANALYSIS OF FIVE PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP (GCLLSG)

Disclosures: PC: research funding by Gilead, GlaxoSmithKline, Hofmann-La Roche and Janssen-Cilag, honoraria for scientific talks by Hofmann-LaRoche and Janssen-Cilag, travel grants by Astellas, Gilead, Hofmann-LaRoche, Janssen-Cilag and Mundipharma. SI: honoraria by Bristol-Myers Squibb and Pfizer, travel grants by Amgen, Hexal, Hofmann-LaRoche and Mundipharma. NP: consultancy for Novartis. GK: travel grants by Celgene and Mundipharma. VG: research funding by Hofmann-LaRoche and Mundipharma, honoraria for scientific talks, consultancy and advisory boards by Bristol-Myers Squibb, GlaxoSmithKline, Hofmann-LaRoche and Mundipharma. MH: research funding by Gilead, GlaxoSmithKline, Hofmann-La Roche and Janssen-Cilag, honoraria for scientific talks, consultancy and advisory boards by AbbVie, Amgen, Gilead, Hofmann-LaRoche and Janssen-Cilag, travel grants by AbbVie, Amgen, Gilead, Hofmann-LaRoche and Janssen-Cilag. JB, SS, MB, MS, EL, PL, AMF, TE KF, CMW and BE: none.

Contributions: PC and SI contributed equally to this manuscript. MH and BE contributed equally to this manuscript. MH was responsible for the conceptual design of all trials and of this metaanalysis. BE, TE, MH and CMW were principal investigators of the trials included in this analysis; MB, HD, BE, TE, VG, MH, MK, EL, SS and CMW recruited patients; HD and SS performed genetic analyses, PC, BE, TE, AMF, KF, VG, MH, GK, SI, PL, NP and CMW coordinated these trials and performed a medical review of the data; PC, BE and SI prepared the data for the statistical analysis and planned the analyses; JB performed the statistical analyses; PC, BE, MH and SI wrote the paper; all authors reviewed and approved the article.